Abstract P6-18-17: Ribociclib + letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population

Autor: Antonio Antón, Santiago González-Santiago, E. Vicente, Joaquín Gavilá, Javier Salvador, R. De Toro, B Cantos Sánchez de Ibargüen, M. Martin, A Gimeno, Meritxell Bellet, Fernando Moreno, L de la Cruz, R. Villanueva Vazquez, E.M. Ciruelos, J de la Haba, Vanesa Quiroga, Noraida Horta Díaz, Agust Barnadas, S Sanz, B. Jiménez-Rodríguez, I. Álvarez, Nerea Martinez, Andreu Prat, J.I. Delgado

Publikováno v: Cancer Research. 79:P6-18

Background: The phase III Monaleesa-2, Monaleesa-3 and Monaleesa-7 trials have shown significantly improved PFS for the combination ribociclib + ET vs ET + placebo in pre-, peri-, and postmenopausal women with HR+/HER2–, first and second line aBC.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b5f38a965a560dee32a365a5568c74a7
https://doi.org/10.1158/1538-7445.sabcs18-p6-18-17

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

Autor: Roberto Torres, P López-Álvarez, Carlos Sampaio, Carlos Barrios, E Villar, Eva Carrasco, A. Lluch, L Pérez-Michel, J.G.M. Segalla, S. Reyes, JA Garcia-Saenz, J. Cárdenas, Maria Jose Godes, M. Ramos, J Castellanos, A. Ruiz, M. J. Escudero, E Martínez de Dueñas, Lourdes Calvo, J Moncayo, J. M. Baena, Manuel Ruiz-Borrego, J. Vinholes, L Torrecillas, Susana Bezares, M. Martin, Henry L. Gomez, Agust Barnadas, M. A. Seguí, Antonio Llombart, Gilberto Luiz da Silva Amorim, J. Bines, Álvaro Rodríguez-Lescure, M Rodríguez de la Borbolla, Antonio Antón, J de la Haba, B Cardemil, E Garcia

Publikováno v: Cancer Research. 79:GS2-04

Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0aebf64b3256301578ee24865dcc030
https://doi.org/10.1158/1538-7445.sabcs18-gs2-04

1719P Clinical characteristics and 28-day mortality among patients with solid cancers and COVID-19 in a tertiary hospital

Autor: Jose Carlos Tapia, J. Gavira, M. Riudavets, Margarita Majem, Ignasi Gich, Oscar J. Ponce, Agust Barnadas

Publikováno v: Europe PubMed Central
Annals of Oncology

Background: The impact of coronavirus disease 2019 (COVID-19) on cancer patients is still unknown We aimed to describe the clinical characteristics and 28-day mortality among patients with solid cancers (SC) and COVID-19 Methods: This single-center r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28afe8b7c01626d80ccd79c4a6632e6
https://doi.org/10.1016/j.annonc.2020.08.1783

Interim results from CompLEEment-1 (A phase IIIb study of ribociclib and letrozole as first-line therapy for advanced breast cancer in an expanded population): Spanish cohort results

Autor: Noraida Horta Díaz, M. Martin, R. De Toro, Eva Ciruelos, Fernando Salvador Moreno, Blanca Cantos, R. Villanueva Vazquez, Vanesa Quiroga, J de la Haba, Antonio Antón, B. Jiménez-Rodríguez, I. Álvarez, I. Delgado Mingorance, Santiago González-Santiago, Javier Salvador, E. Vicente, Agust Barnadas, Nerea Martinez, L. De La Cruz, M. Bellet Ezquerra

Publikováno v: Annals of Oncology. 30:v119-v120

Background In Spain luminal metastatic Breast Cancer accounts for more than 3000 deaths yearly. Ribociclib+letrozole has shown efficacy on prolonging progression free survival (PFS) vs placebo+letrozol in two phase 3 trials. However, data on efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e96e4991f301927c7c850f9491e3461
https://doi.org/10.1093/annonc/mdz242.031

A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

Autor: Francisco Ayala, Carlos A. Rodriguez, Lourdes Calvo, A. Lluch, Andrés Redondo, Agust Barnadas, A. González, Antonio Antón, J. de la Haba, Antonio Llombart, J. M. López-Vega, Eva Ciruelos, Joan Albanell, Javier Cortes, Isabel Alvarez, I. Peláez, E. Aba, Montse Muñoz, Á. Rodríguez, A. Ruiz, Eduardo Martínez

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA

To converge on an expert opinion to define aggressive disease in patients with HER2-negative mBC using a modified Delphi methodology. A panel of 21 breast cancer experts from the Spanish Society of Medical Oncology agreed upon a survey which comprise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::affefa4d038e1bdfd6683e8805500cd2
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=1585